Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Safety, Pharmacokinetic, and Efficacy Study of the Combination of Miglustat for the Treatment of CLN3 Disease in Patients 17 Years of Age and Older

NCT05174039 is registered in ClinicalTrials.gov with Beyond Batten Disease Foundation as lead sponsor.

NCT NCT05174039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05174039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Safety, Pharmacokinetic, and Efficacy Study of the Combination of Miglustat for the Treatment of CLN3 Disease in Patients 17 Years of Age and Older
Lead sponsor
Beyond Batten Disease Foundation
Phase
Phase 1/2
Overall status
Completed
Start date
March 10, 2022
Completion date
May 30, 2024
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

batten disease